Source : DRAUP
1
1
Johnson & Johnson – Account Deep Dive
Analysis
October 2018
Source : DRAUP
2
2
AGENDA
➢ Johnson & Johnson Overview
❑ Highlights on Johnson & Johnson, business overview
❑ Last 5 years revenue analysis
❑ Revenue split by geography
❑ Key operating business segment
➢ Organization Structure
❑ CXO’s and Executives
Rolodex04
Account Profile
Business & Financial Overview
Outsourcing Vendor Analysis
Globalization Footprint
Recommendations05
01
02
03
Source : DRAUP
3
3
On October 2, 2018 Johnson & Johnson completed the divestiture of its LifeScan business to Platinum Equity for approximately $2.1 billion
Revenue in $ billion R&D spend in $ billion
Johnson & Johnson, together with its subsidiaries,
researches and develops, manufactures, and sells
various products in the health care field worldwide. It
is an American multinational medical devices,
pharmaceutical and consumer packaged goods
manufacturing company.
About Johnson & Johnson
Note – DRAUP data curated from Johnson & Johnson financial reports published annually and updated in October, 2018
Revenue (2017):USD $ 76.45 billion
R&D Spend (2017):USD $ 10.55 billion
Headquarter:New Brunswick, New Jersey,
United States
Year of Establishment:1887
Revenue vs R&D spend (2013-17)
Revenue CAGR
(2013 - 2017):1.76%
R&D CAGR
(2013 - 2017):6.57%
Revenue share by segment (2017)
Employees (2017):~ 1,34,000
Revenue share by Geography (2017)
52%
22%
18%
8%
United States
Europe
Asia-Pacific, Africa
WesternHemisphere
Pharmaceutical47%
Medical devices35%
Consumer18%
$71.31 $74.33
$70.07 $71.89 $76.45
$8.18 B $8.49 B $9.04 B $9.09 $10.55
2013 2014 2015 2016 2017
Source : DRAUP
4
4
Johnson & Johnson – Business Segments Overview
Johnson & Johnson
Accelerant
Note – DRAUP data curated from Johnson & Johnson financial and analysts reports published annually and updated in October, 2018
ACUVUE Adjunctive HemostasisAccessAdvanced Sterilization
Products (ASP)
Automotive Experience Building EfficiencyChemical Process
Equipment's & EngineeringBiosense Webster Cordis
DePuy SynthesEnergy Sealing and
DissectingHernia Mesh & FixationDiabetes Care Ligation
Mentor One Touch Power SolutionsMicrowave Ablation Surgical Stapling
Vascular Access and
Infection ControlWound ClosureUterine & Pelvic
Source : DRAUP
5
5
Johnson & Johnson – Executive Leadership
Joaquin DuatoVice Chairman of the Executive Committee
Peter FasoloExecutive Vice President, Chief Human Resources
Officer
Ashley McEvoyExecutive Vice President, Worldwide Chairman,
Medical Devices
Jennifer TaubertExecutive Vice President, Worldwide Chairman,
Pharmaceuticals
Michael SneedExecutive Vice President, Global Corporate Affairs &
Chief Communication Officer
Paul StoffelsVice Chair of the Executive Committee and Chief
Scientific Officer
Note – The above analysis is based on the DRAUP’s Executive Module, updated in October, 2018.
Alex Gorsky
Chairman, Board of Directors &
Chief Executive Officer
Jorge MesquitaExecutive Vice President, Worldwide Chairman,
Consumer
Michael UllmannExecutive Vice President, General Counsel
Kathy Wengel Executive Vice President & Chief Global Supply Chain
Officer
Joseph J. WolkExecutive Vice President, Chief Financial Officer
Source : DRAUP
6
6
KEY STRATEGIC PRIORITIES: Core Business Initiatives & Organisational Restructuring
• On September 12, 2018 Johnson & Johnson Medical Devices through its subsidiary Johnson & Johnson Medical GmbH acquired Emerging Implant Technologies GmbH (EIT), a privately held
manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery that allowed DePuy Synthes to enhance its comprehensive interbody implant portfolio that includes expandable
interbody devices, titanium integrated PEEK technology and now 3D-printed cellular titanium, for both minimally invasive and open spinal surgery.
• On July 30, 2018 Johnson & Johnson Consumer Inc. acquired Zarbee’s, Inc., a privately held company that is a leader in naturally-based healthcare products to bring a more comprehensive set
of products to consumers within their core need states.
• On June 12,2018 Johnson & Johnson announced that it has accepted the binding offer from Platinum Equity, to acquire its LifeScan, Inc., a world leader in blood glucose monitoring and maker
of the OneTouch® brand of products to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses
• On June 6, 2018 Johnson & Johnson announced that it has received a binding offer from Fortive Corporation to acquire its Advanced Sterilization Products (ASP) business, a division of
Ethicon, Inc to deliver the greatest value to customers, healthcare providers and shareholders.
• On May 2,2018 Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, acquired BeneVir Biopharm, Inc., a privately-held, biopharmaceutical company
specializing in the development of oncolytic immunotherapies which focused to bring forward an array of novel immunotherapies and combinations that might improve treatment outcomes for
patients.
• On February 20, 2018 Johnson & Johnson Medical Devices Companies acquired Orthotaxy, a privately-held developer of software-enabled surgery technologies to build a next-generation
robotic-assisted orthopaedic surgery solution that is cost-effective, time-efficient, and user-friendly in a variety of care settings
Note – Analysis is based on the news articles, journals and other similar sources updated in October, 2018
• On August 8, 2018 Johnson & Johnson announced the appointment of Chris DelOrefice as Vice President of Investor Relations to provide strategic financial leadership and counsel.
• On June 22, 2018 Johnson & Johnson announced the appointment of Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals and Dr. Paul Stoffels, Executive Vice
President, Chief Scientific Officer to the position of Vice Chairman of the Executive Committee
Organisational Restructuring
Core Business Initiatives
Source : DRAUP
7
7
KEY STRATEGIC PRIORITIES: Focus on Emerging Technologies & Ecosystem Partnerships
Focus on Emerging Technologies
Note – Analysis is based on the news articles, journals and other similar sources updated in October, 2018
• On September 26, 2018 Johnson & Johnson announced that DePuy Synthes introduced
SENTIO MMG, a first-of-its-kind digital mechanomyography platform designed to assess
nerve status and identify and avoid peripheral nerves during spine surgery.
• On June 7, 2018 DePuy Synthes, part of the Johnson & Johnson Medical Devices
Companies announced the launch of its Femoral Recon Nail System, a nailing system that
provides new options for the surgical treatment of a wide variety of long thigh bone fractures.
• On April 26,2018 DePuy Synthes, part of the Johnson & Johnson Medical Devices
Companies announced the US launch of the PROTI 360° Integrated Titanium Family of
interbody devices to advance care for patients who have degenerative disc disease in the
neck and back.
• On April 11, 2018 Johnson & Johnson Vision announced ACUVUE OASYS® with
Transitions® Light Intelligent Technology™ first of its kind contact lens that provides
wearers with vision correction and a dynamic photochromic filter that helps to continuously
balance the amount of light entering the eye
• On April 5, 2018 Johnson & Johnson Institute added a Innovative Analytics-Based
Learning Platform , a new digital learning capability to help surgeons improve technical
skills and clinical outcomes Across a Range of Specialties
• On September 23, 2018 Johnson & Johnson collaborated with Janssen Vaccines &
Prevention B.V., part of the Janssen Pharmaceutical Companies to develop and
manufacture a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-
CoV).
• On August 7, 2018 Johnson & Johnson Services Inc. partnered with the Government of
Rwanda to significantly strengthen and expand access to quality mental health care in the
country
• On April 16, 2018 The Janssen Pharmaceutical Companies of Johnson & Johnson
collaborated with Bristol-Myers Squibb Company on a program to develop and
commercialize Factor XIa (FXIa) inhibitors, including BMS-986177 for the prevention and
treatment of major thrombotic conditions.
• On February 7, 2018 The Janssen Pharmaceutical Companies of Johnson &
Johnson collaborated with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, a
first-in-class oral, gastrointestinal (GI) restricted pan-Janus kinase (JAK) inhibitor for the
treatment of inflammatory bowel disease (IBD), which includes Crohn’s disease and
ulcerative colitis (UC).
• On December 21, 2017 Janssen Biotech, Inc. collaborated with Legend Biotech USA Inc.
and Legend Biotech Ireland Limited, subsidiaries of Genscript Biotech Corporation, to
develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug
candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen (BCMA).
Ecosystem Partnerships
Source : DRAUP
8
8
AGENDA
➢ Details on Global Technology Footprint
❑ Key buying locations
❑ Region wise insights for global Technology centres – Headcount,
Activities and key products developed
Account Profile
Business & Financial Overview
Outsourcing Vendor Analysis
Globalization Footprint
Rolodex04
Recommendations05
01
02
03
Source : DRAUP
9
9
Key Buying Locations
➢ Key buying center is based out of Greater New York Area, United States
➢ Greater New York Area, United States with ~16% of engineering talent, is responsible for the development, maintenance
and execution of test scripts/ test cases for System integration test across test phases based on business requirements,
functional requirement specification and User stories
Key Engagements
➢ The Key activities are definition, implementation and maintainenance of program management strategies, procedures,
processes, and methodologies.
➢ Establishment and maintainenance of a Global Pharma Application/Service Asset & Configuration Management (SACM)
Governance process.
➢ Development of a of Tolerance Analysis System using TADM (Tolerance Analysis and Dimensional Management) System and
Enventive®
➢ Development and implementation of multi-region projects that drive strategic plan objectives for high growth of Clean & Clear®,
Beauty Devices, and the broader Johnson & Johnson® Face Care portfolio of brands.
Key StakeholdersMargaret Yu
Vice President, Oncology Clinical
Development
Dan BakerVice President Immunology
R&D
Kendra HilemanVP, Head of Clinical R&D
Daniel ZelemChief Technology Officer
Summary: Johnson & Johnson – Technology Globalization Footprint
Note – Analysis is based on the news articles, journals and other similar sources updated in October, 2018
Source : DRAUP
10
10
Global Technology Footprint of Johnson & Johnson
22Total Number of Technology Hotspots
3,000 – 4,000Total Number of Technology workforce
Installed
1Number of Buying Centers
Note – The represented data has been collected from Draup Proprietary Global Footprint Database updated as of October, 2018.
Note: The represented data illustrates the number of centers by Geography and the bubble size is proportional to overall HC Installed in the area.
No. of Centers : 1
Head Count : 30 – 60
Ireland
No. of Centers : 14
Head Count : 2K – 3K
No. of Centers : 1
Head Count : 200 – 250
No. of Centers : 2
Head Count : 200 – 300
Johnson & Johnson : Greater New York Area, United States is the only Key Buying Center that owns 100% of total Outsourced deals
United
States of
America
Switzerland
No. of Centers : 1
Head Count : 200 – 300
UK
No. of Centers : 1
Head Count : 50 – 100
Germany
No. of Centers : 1
Head Count : 50 – 100
Israel
China
No. of Centers : 1
Head Count : 20 – 30
Netherlands
Source : DRAUP
11
11
Outpost
Satellite
Hub
Note – The represented data has been collected from Draup Proprietary Global Footprint Database updated as of October, 2018.
Johnson & Johnson : Greater New York City Area, United States is one of the major Engineering hubs that owns ~16% of total Technology Workforce
Inverness Area
Greater New York City
Ireland
Cincinnati Area
Orange Country
Greater Philadelphia Area
Jacksonville, Florida
San Francisco Bay Area
Leeds Area
Israel
SwitzerlandGreater Boston Area
Greater Los Angeles
Hamburg Area
Fort Wayne, Indiana AreaMiami/Fort Lauderdale
Suzhou, China
Albuquerque, New Mexico Area
Groningen Area
San Angelo, Texas Area
Madison, Wisconsin Area
Providence, Rhode Island Area
Source : DRAUP
12
12
Location
Greater New York City
Area, United States
R&D Headcount
500 – 600 FTEs
Center Level
Hub, HQ
Average Salary Cost / FTE
USD 115K / Annum
• Creation of Python-Flask REST API’s health-check endpoints to fetch data from HashiCorp Consul for granular
level monitoring Web, DB, Node.js app services to showcase real time statistics on Grafana Dashboard.
• Implementation of TDD/BDD approach for developing the Python applications, unit-tested by mocking for external
resources like AWS S3 Bucket, DynamoDB, VMware vRealize Orchestrator's API's slashing resource.
• Development of innovative plastic surgery implants, reconstruction & augmentation silicone based implants
• Validation of data on front end as well as Back end (Writing Sql Query).
• Development of biochemical and physical assays to characterize formulations of novel medical devices.
• Mechanical device design and development for Wound Closure and Repair, Hernia, and Bio surgery businesses
Top leaders
Daniel ZelemChief Technology Officer
MaryJo ZaborowskiVice President, R&D IT
Major Engineering Talent Profiles
Senior Data
analyst
Note – The above analysis is based on the DRAUP’s Executive Module, updated in October, 2018
Greater New York City Area, United States – Technology Centre Deep Dive: Centre Overview
Software
Engineer
Source : DRAUP
13
13
Technology Leadership
42 Key Executives (Including, Top Leaders, VPs and Directors)
Top Leaders
Vice president’s
Daniel ZelemChief Technology Officer
Bernhard BrouwerVP IT - Consumer NA + global
R&D
Norm RosenthalVP, Clinical Development,
Cardiovascular & Metabolism
Josh GhaimChief Technology Officer at
Johnson & Johnson
Note – The above analysis is based on the DRAUP’s Executive Module, updated in October, 2018
Katia BovenVP, Clinical Development and
Global Medical Affairs
San Francisco Bay Area, United States – Technology Centre Deep Dive: Technology Leadership (1/3)
MaryJo ZaborowskiVice President, R&D IT
Sen Zhuang MDVice President, Oncology
Clinical Research
Vaibhav NarayanVP Research and Therapeutic
Area IT
Walter JoppyVP Global IT Quality &
Compliance
Lynn ReedVP, Information Technology,
Application Services
Jonathan MillerVP Global Oral Care & Wound
Care R&D
Gunaretnam RajagopalVP - Global Head,
Computational Sciences,
Discovery Sciences
Samantha Tucker-
SamarasVP, Strategic Science R&D
Jennifer ZhuVice President, Global Beauty
R&D
Source : DRAUP
14
14
Technology Leadership
42 Key Executives (Including, Top Leaders, VPs and Directors)
Vice President’s
Note – The above analysis is based on the DRAUP’s Executive Module, updated in October, 2018
Federico Feldstein, JDVice President, Head of R&D
Quality & Compliance
David GruberVP, Corporate Development &
New Ventures
Leona Brenner- GatiVice President, Science and
Technology
Keith DemarestVice President, Global Head of
Research
San Francisco Bay Area, United States – Technology Centre Deep Dive: Technology Leadership (2/3)
Director’s
Nicholas Di ProsperoSenior Director, Clinical
Development
Muneet BurkeDirector - Medical Safety Officer
Christoph HeuckSenior Director Clinical
Research
Mehul DesaiSenior Director Clinical
Development
Om Sharma, MSDirector, Clinical Research and
Drug Development
Eunice Ofori ArtisDirector, Clinical Research
Rafal HRYMOCDirector - Global R&D Beauty
Packaging & Innovation
Carolyn MordasSenior Director R&D
Jacqueline BussolariSenior Director, Development
Team (Oncology)
Phil Rudio, PEGlobal Director, Engineering and
Design
Filomena MacedoSenior Director R&D Skin Care
Theresa ScheubleDirector, R&D
Michael SmithSenior Director, Compound
Development Team
Charles J. BuckleDirector of Engineering
Rochelle KleinbergDirector, Healthcare Solutions
Chris KarcherDirector, Enabling Technology
Source : DRAUP
15
15
Technology Leadership
42 Key Executives (Including, Top Leaders, VPs and Directors)
Note – The above analysis is based on the DRAUP’s Executive Module, updated in October, 2018
San Francisco Bay Area, United States – Technology Centre Deep Dive: Technology Leadership (3/3)
Director’s
Cokey N.Senior Director, Oncology R&D
Mayra GoncalvesSenior Director R&D
George QuirkSenior Director, Engineering
Network
Ying WanDirector, Oncology Clinical
Biostatistics
John MurthaDirector Material Science &
Technology
Steven GabelDirector, Engineering
Carol BoyneSenior Director R&D
Pat CalaiaroDirector, R&D Operations
Source : DRAUP
16
16
DETAILSLOCATIONR&D
HEADCOUNT
Greater New York City
Area, United States500 – 600
• Development of Jenkins CICD pipelines, automating deployments for (AWS & Bare metal VM’s), integration with GIT to
automate code-checkout and release processes.
• Involved in Research and Development of Sutures including Antibacterial Sutures
Greater Philadelphia
Area, United States400 – 450
• Product development of digital solutions for the Johnson & Johnson Diabetes Care companies, including LifeScan Inc.,
Animas Corporation, and Calibra Medical, Inc
• Design and develop implants and instrumentation for orthopaedic applications
Cincinnati Area,
Kentucky, United
States
300 – 400
• Supports the Ethicon Portfolio of Products in J&J Medical Devices.
• Design and development of Harmonic products in the Energy business
• Development of bipolar and ultrasonic algorithms for optimum tissue sealing effects
Jacksonville, Florida
Area, United States300 – 400
• Design and management of biomarker discovery for ophthalmic indications and contact lens derived adverse events.
• Leads and manages the Global R&D Lab Systems Production Line.
• Product development in spherical daily disposable and reusable lenses, lenses for astigmatism, lenses for presbyopia,
and lenses for natural beauty enhancement
Switzerland 200 – 250• Validation of Equipment Process/Aseptic Process Simulation in Life Cycle Management of Parenterals Production.
• Development of products for cervical spine treatment & Cervical R&D
Ireland 200 – 250
• Development, testing and installation of control system software changes with supporting documentation for validating
the manufacturing systems.
• Development and execution of test plans (SAT, FAT).
Globalization Technology Footprint (1/4)
Note – Global Footprint data curated by DRAUP and updated in October, 2018. R&D Headcount includes research and product engineering talent
Buying Centres
Source : DRAUP
17
17
DETAILSLOCATIONR&D
HEADCOUNT
Greater Boston Area,
United States100 – 200
• Development of new and novel Spinal systems including MIS Pedicle Screws, Power, Navigation, Expandable Cages, 3D
Printed cages and Lateral Systems.
• Involved in Process Development for Health Care Products
Greater Los Angeles
Area, United States100 – 200
• Development of the Clean & Clear® brand by ensuring global consistency in Generation Z equity understanding,
positioning, new product idea generation to drive the business growth.
• Identify and capitalize on key macro trends for leading key global strategic Face Care initiatives
Orange County,
California Area, United
States
100 – 200
• Validation of Enterprise systems with preparation and execution of validation deliverables. Supports Product Quality
NPI/LCM projects.
• Development of test methods, creates protocols and analyses data.
Inverness, United
Kingdom100 – 150
• Validation and Verification of high-tech automated manufacturing line of networked machines.
• Creation and execution of validation documents, specifically factory acceptance testing protocols.
• Deployment of strategic NPI’s & Supply Chain projects into the organisations product portfolio.
San Francisco Bay
Area, United States100 – 150
• Involved in end-of-life mitigation, service escalations and cost improvement projects for on-market products.
• Involved in PCBA design changes for product yield improvement
Hamburg Area,
Germany50 – 100
• Planning, implementation & sustainability of process improvements in relation to material and productivity losses of a
surgical sutures production area.
• Supports QMS related projects such as integrating the EES GmbH Quality System into the Ethicon Quality System.
Globalization Technology Footprint (2/4)
Note – Global Footprint data curated by DRAUP and updated in October, 2018. R&D Headcount includes research and product engineering talent
Source : DRAUP
18
18
DETAILSLOCATIONR&D
HEADCOUNT
Leeds, United Kingdom 50 – 100
• Development of appropriate orthopaedic medical devices specifically for the ASPAC region.
• Management of the project from the front end, charter, development, verification and validation through to eventual
commercialisation
Israel 50 – 100
• Development of firmware for a generator device used for Cardiac ablation procedure.
• Design, development & implementation of Software & Architecture for Advanced Networking and Wireless Devices in
embedded platforms
Fort Wayne, Indiana
Area, United States40 – 80
• Development of New technology and involved in next generation biological fixation.
• Design/optimize stainless steel surgical instruments for 3D Printing.
• Planning and designing of Post processing of parts for machining, heat treatment and use of finishing technologies.
Miami/Fort Lauderdale
Area, United States40 – 80
• Design and maintainenance of ETL processes and data warehouse.
• Development and implementation of processes, procedures, audits and corrective actions.
• Design and implementation of machine safeguards.
Suzhou, China 30 – 60
• Creating 3D models, drawings, DFMEA and DHF.
• Designing of global joint to meet the need and requirement of Chinese market and performs unique product development
process to create domestic product codes with high standard drawings
Albuquerque, New
Mexico Area, United
States
10 – 30• Involved in several different product lines and all New Product Development launches.
• Development of diagnostic technologies for refractive & cataract surgery and contact lenses.
Globalization Technology Footprint (3/4)
Note – Global Footprint data curated by DRAUP and updated in October, 2018. R&D Headcount includes research and product engineering talent
Source : DRAUP
19
19
DETAILSLOCATIONR&D
HEADCOUNT
Groningen Area,
Netherlands10 – 30
• Development of Intraocular lenses for cataract surgery.
• Performs overall QA activities in a medical devices company with slight focus on Quality Management System.
San Angelo, Texas
Area, United States10 – 30
• Testing and inspection of the quality of chemical compounds, reagents and culture media.
• Development and implementation of the Reliability and Maintenance Engineering Department.
Madison, Wisconsin
Area, United States10 – 20
• Testing and running of protocols that help characterize performance of NeuWave technology.
• Involved in new product launch to accelerate the business growth.
Providence, Rhode
Island Area, United
States
10 – 20
• Development and delivery of multiple Android platforms including Care4Today Connect, the J&J Official 7 Minute
Workout, and applications developed for the Care Module platform.
• Automation of regression tests for numerous company projects using JBehave /Java, and similar tools.
Globalization Technology Footprint (4/4)
Note – Global Footprint data curated by DRAUP and updated in October, 2018. R&D Headcount includes research and product engineering talent
Source : DRAUP
20
20
AGENDA
➢ Outsourcing Vendor’s deals analysis
❑ Total headcount outsourced to service providers
❑ Key vendors working with Johnson & Johnson
❑ Key Opportunity areas to target
Account Profile
Business & Financial Overview
Outsourcing Vendor Analysis
Globalization Footprint
Rolodex04
Recommendations05
01
02
03
Source : DRAUP
21
21
Summary: Technology Services Outsourcing
Key partners
Key Activities
➢ Product Engineering Services is the key engagement areas for Johnson & Johnson contributing to 55% of total outsourced
deals
➢ Major workloads across Product Engineering Services is development & Testing of some mobile application like Nicorrete,
mentor App etc.,
➢ Involved in Adhoc Testing, Sanity Testing, Functional Testing and Regression testing.
Note: Analysis is based on the news articles, journals etc updated in October, 2018
Key Opportunity Areas➢ Vendors should target on Product Engineering Services related engagements
➢ Vendors can also target on Artificial Intelligence (AI) for the discovery of Drugs
➢ HCL is the major strategic partner for Johnson & Johnson working majorly across the area of PES, ADM and IMS. HCL
contributing to ~40% of total outsourcing size
➢ TCS is other key outsourcing partner contributing to nearly ~30% of the current outsourced deals
Source : DRAUP
22
22
HCL 40%
TCS 30%
Cognizant 12%
Capgemini, 9%
Sonata Software, 5%
IBM, 2%Wipro, 2%
Technology Outsourcing Split by Service ProvidersSplit by Sub Service Segment (In HC %)
400 - 450 Workforce split across
Outsourcing Partners
7 Active Outsourcing Partners
Note - Above analysis is based on the DRAUP’s proprietary Outsourcing module, updated in October, 2018.
Vendor Analysis – HCL is the major strategic partner for Johnson & Johnson contributing to 40% of total outsourced HC
Source : DRAUP
23
23
ADM and IMS Sub-segments has the highest number of deals with multiple vendors
Note - Above analysis represents the HC split of Service Providers in each Sub-segment for Johnson & Johnson updated in October, 2018
Cognizant, 46% HCL, 18% Sonata Software, 9% TCS, 18% Wipro, 9%
Cognizant HCL Sonata Software TCS WiproADM
Capgemini, 17% HCL, 17% IBM, 17% Sonata Software, 17% TCS, 32%
Capgemini HCL IBM Sonata Software TCSIMS
PES
Capgemini, 13% HCL, 60% TCS, 27%
Capgemini HCL TCS
TCS, 100%
TCSCSI
Source : DRAUP
24
24
Key Vendor Engagements Snapshot (1/3)
Note - Above analysis is based on the DRAUP’s proprietary Outsourcing module, updated in October, 2018.
Split of Workforce by Sub Segment
PES :
• Designing, Testing, development & Maintenance of pheonix STNX
• Implementation of 3D Model design & evaluation
ADM :
• Involved in executing the Test Protocols
• Preparation of Test Protocol for the verification testing
IMS:
• Monitoring batch jobs using SCOM,NETCOOL and NCS Alert board
• Installation of Windows & Unix agent, Cluster package (Windows & Unix).
HC
100 – 200
Key Delivery Locations
Delhi, Madurai, Chennai
ADM, 12% IMS, 6% PES, 82%
Split of Workforce by Sub Segment
ADM:
• Involved in implementing UI changes
• Development of functional specifications document and technical design document
CSI:
• Development of POC for S&OP & supply chain visibility using SAP IBP
• Creation of Information Models like Attribute View, Calculation View, Analytic View
PES:
• Development & testing of some mobile application like Nicorrete, mentor App etc
• Supports the US FDA Submission batches
IMS:
• Development of Tcl & SQL scripts to generate reports and modify data as per requirements as post-load activity
HC
100 – 150
Key Delivery Locations
Bengaluru,
Bhubaneshwar, Kolkata
ADM, 16% CSI, 16% IMS, 16% PES, 52%
Source : DRAUP
25
25
Key Vendor Engagements Snapshot (2/3)
Note - Above analysis is based on the DRAUP’s proprietary Outsourcing module, updated in October, 2018.
ADM:
• Involved in System, Integration, Automation, Regression and Mobile Testing
• Development of HTML Pages for Ipad Compatibility and Page Level interactions
ADM, 100%
Split of Workforce by Sub Segment
PES:
• Enhancement & Support for web based applications
• Development, Testing, upgradation for JNJ products like GEN11 devices, Ethicon App
IMS:
• Involved in Data Modelling, Data Quality and loading strategy
HC
20 – 40
Key Delivery Locations
Bengaluru
IMS, 25% PES, 75%
Split of Workforce by Sub Segment
ADM:
• Debugs the test scripts to identify the scripts errors and fix the errors
• Enhancement of automation framework and updating the test scripts based on the changes in the received in different sprints
IMS:
• Designing the test Cases for validating JJAR database
• Testing JJAR reports and validating the data in reports
HC
10 – 20
Key Delivery Locations
Hyderabad, Bengaluru
ADM, 50% IMS, 50%
Split of Workforce by Sub Segment
HC
30 – 60
Key Delivery Locations
Bengaluru, Howrah
Source : DRAUP
26
26
Key Vendor Engagements Snapshot (3/3)
Note - Above analysis is based on the DRAUP’s proprietary Outsourcing module, updated in October, 2018.
Split of Workforce by Sub Segment
ADM:
• Development of RFP Import from GB to Ariba Buyer
• Involved in Application Packaging and Integration
• Development of web services to call web method from Infosys’ Procure Edge to Ariba
HC
10 – 20
Key Delivery Locations
Bengaluru
ADM, 100%
Split of Workforce by Sub Segment
IMS:
• Involved in agile sprint planning and story grooming sessions
• Development of the mapping/ sessions/ workflows for learning assignment module
• Involved in performance tuning issues at various levels such as target, sessions, mappings and sources
HC
10 – 20
Key Delivery Locations
Kolkata
IMS, 100%
Source : DRAUP
27
27
AGENDA
➢ Key Technology Stakeholders
❑ Key Technology stakeholders & Leadership
Account Profile
Business & Financial Overview
Outsourcing Vendor Analysis
Globalization Footprint
Rolodex04
Recommendations05
01
02
03
Source : DRAUP
28
28
Johnson & Johnson – Technology Leadership (1/2)
Norm RosenthalVice President, Clinical Development,
Cardiovascular & Metabolism
Philippe SzaparyVice President, Immunology Clinical
Development
Michael EppihimerVice President of Preclinical Research
Bernhard BrouwerVP IT - Consumer NA + global R&D
Katia BovenVice President, Clinical Development
and Global Medical Affairs, Infectious
Diseases
Daniel Zelem
Chief Technology Officer
Margaret YuVice President, Oncology Clinical
Development
Note – The above analysis is based on the DRAUP’s Executive Module, updated in October, 2018.
Ian McCafferyVice President, Head Oncology
Translational Research
Jeremy YarwoodVice President of Research and
Development, Advanced Sterilization
Products
MaryJo ZaborowskiVice President, R&D IT
Vaibhav NarayanVP Research and Therapeutic Area IT
Julian BertschingerVP, Head Therapeutic Platform
Innovation
Kendra HilemanVP, Head of Clinical R&D
Dave SmithVice President, Global Research and
Development
Sal TrovatoVice President, Corporate IT Global
Product Line
Dirk GilleVP R&D Fellowship Development
Leader
Sen ZhuangVice President, Oncology Clinical
Research
Anastasia ChristiansonVice President, R & D Operations and
Oncology IT
JD AlvarezVice President and Head, Oncology
Diagnostics
Samantha Tucker-SamarasVice President, Strategic Science R&D
Scott PlevyVice President, Immunology Research
and Development
Source : DRAUP
29
29
Johnson & Johnson – Technology Leadership (2/2)
David GruberVP, Corporate Development & New
Ventures
Note – The above analysis is based on the DRAUP’s Executive Module, updated in October, 2018.
Leona Brenner-GatiVice President, Science and Technology
Brian WoodfallVice President, Global Clinical
Development
Vake JozefVice-President Non-Clinical Development
Bonnie SiegelVice President Information Technology
Bob RadinskyVice President, Oncology Scientific
Innovation
Kiran PatelVice President Clinical Development
Gopi ShankarVice President & Head, Biologics
Development Sciences
Dan BakerVice President Immunology R&D
David WoodsVP of Product Engineering, Health
Technology
Martin Madden Vice President, Research & Development,
and Innovation
Peter CorsoVice President, Information Technology,
Medical Devices Global Product Lines
Federico FeldsteinVice President, Head of R&D Quality &
Compliance
Claudia HerbenVice President IT and CIO Medical
Device
Kenny SimmenVP - Infectious Diseases & Vaccines
Ian AndersonSenior Vice President Immunology
Discovery and Scientific Innovation
Patricia Andrade-GordonVice President Early Development
Keith DemarestVice President, Global Head of Research
Source : DRAUP
30
30
AGENDA
➢ Key Opportunities
❑ Orthotaxy’s technology
❑ AI Drug Discovery
Account Profile
Business & Financial Overview
Outsourcing Vendor Analysis
Globalization Footprint
Rolodex04
Recommendations05
01
02
03
Source : DRAUP
31
31
By analysing Johnson & Johnson focus, DRAUP has identified the following key opportunity areas
Key Opportunity Segments
Note - Above analysis is based on the DRAUP’s proprietary services module, updated in October, 2018.
By the acquisition of Orthotaxy Johnson & Johnson
continues the development of the differentiated
robotic-assisted tool first for total, partial knee
replacement and also for multiple orthopaedic
surgery procedures such as spinal fusion surgery
Johnson & Johnson is planning to expand
Orthotaxy’s technology into other orthopaedic
surgeries as part of its bid to create a new robot-
assisted to personalize procedures, optimize
surgery and also to bring value to customers and
patients
Orthotaxy’s Technology
Johnson & Johnson invested up to $1M in
Artificial Intelligence for Drug Discovery
QuickFire Challenge as AI poses unlimited
opportunity for J&J to make a transformative impact
on patients.
Janssen Research & Development found a new
way to leverage artificial intelligence (AI) by
using computer systems and also teamed up with
academic partners from leading European
universities to develop computer algorithms
AI Drug Discovery
Source : DRAUP
32
32